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Summary
Background: Inhibitors of the renin angiotensin system are recommended as the ﬁrst-line med-
ications for diabetic hypertensive patients. However, there is less evidence supporting this
recommendation especially among East Asians, a population with a unique distribution of
cardiovascular disease compared to the Western population.
Methods and results: The NAGOYA HEART Study is a prospective randomized open-label blinded-
endpoint study to compare an angiotensin II receptor blocker, valsartan, and a calcium channel
blocker, amlodipine, regarding their efﬁcacies on cardiovascular morbidity and mortality in
Japanese hypertensive patients with glucose intolerance. Of 1168 eligible patients, we enrolled
1150 patients from October 2004 to January 2009. The participants will be followed for moremortality and
morbidity
than a median follow-up period of 3 years. The primary composite endpoint includes myocar-
dial infarction, stroke, coronary revascularization, and admission due to congestive heart failure
or sudden cardiac death. Any of these events are adjudicated by an independent committee
under blinded information regarding the treatment arm. Secondary endpoints include all-cause
e tolerance status, kidney function, left ventricular structure mea-mortality, changes in glucos
sured by echocardiogram, and incident atrial ﬁbrillation/ﬂutter. The study was registered at
ClinicalTrials.gov NCT00129233.
∗ Corresponding author. Tel.: +81 52 744 2149; fax: +81 52 744 2138.
E-mail address: murohara@med.nagoya-u.ac.jp (T. Murohara).
0914-5087/$ — see front matter © 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusion: The NAGOYA HEART Study will provide us with a relevant insight for appropriate
treatment of hypertension with glucose intolerance.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ejection fraction less than 40%; (4) second- or third-degree
atrio-ventricular block; (5) severe hypertension (systolic orntroduction
ypertensive patients with type 2 diabetes mellitus (T2DM)
ave almost 2-fold higher risk for suffering from ischemic
ardiovascular diseases compared to non-diabetic hyperten-
ive patients [1]. Inhibitors of the renin angiotensin system
i.e. angiotensin-converting enzyme inhibitors (ACEIs) or
ngiotensin II receptor-1 blockers (ARBs)] are widely
ecommended as the ﬁrst-line medications for diabetic
ypertensive patients in clinical guidelines issued by most
eveloped countries [1—4]. This is because many clini-
al trials [5—8], but not all [9—11], have suggested that
CEIs and/or ARBs protect more effectively against the
evelopment of macrovascular and microvascular diseases
ompared to other types of antihypertensive drugs in this
articular patient population.
Angiotensin II plays pivotal roles in the development of
ypertension and vascular complications by inducing vaso-
onstriction, sodium and water retention, smooth muscle
ell proliferation, myocardial ﬁbrosis, superoxide forma-
ion, plasminogen activator inhibitor-1 production, and
ctivation of the sympathetic nervous system [12—14].
mportantly, angiotensin II also reduces insulin sensitivity
ossibly through the inhibition of intracellular insulin sig-
aling [12]. In fact, ACEIs and/or ARBs have been shown to
revent new onset of T2DM in many clinical trials [6,15].
herefore, there is a concrete background supporting par-
icular beneﬁts of ACEIs and/or ARBs for the treatment
f hypertensive patients with glucose intolerance [i.e.
mpaired glucose tolerance (IGT) or T2DM].
The epidemiology of cardiovascular diseases in Japan
s different from that typically observed in Western coun-
ries. In particular, the age-adjusted incidence rate of
schemic heart disease in Japan is almost 80% lower than
hat in the USA [16]. In contrast, mortality rate due to
troke is 3—4-fold higher in Japan compared to the USA
16,17]. Given the fact that calcium channel blockers (CCBs)
re useful for the prevention of stroke [18], one may
ssume that CCBs are more beneﬁcial for Japanese hyper-
ensive patients with T2DM or IGT. Regarding the incidence
f heart failure, Japanese have a higher mortality rate
ue to heart failure compared to the Western population
17]. Since inhibitors of the renin angiotensin system can
ffectively prevent the development of heart failure com-
ared to other antihypertensive drugs [19], ACEIs and/or
RBs may be beneﬁcial to Japanese patients in this con-
ext.
Taken together, it is still unclear whether inhibitors of
he renin angiotensin system can prevent adverse compos-
te cardiovascular events more effectively than CCBs in
apanese hypertensive patients with T2DM or IGT. Accord-
ngly, we designed a clinical trial comparing an ARB,
alsartan, and a CCB, amlodipine, with respect to their
fﬁcacies on cardiovascular morbidity and mortality in
d
r
n
l
wapanese hypertensive patients with glucose intolerance
T2DM or IGT).
ethods
tudy design
he NAGOYA HEART Study is a multicenter study apply-
ng a prospective randomized open-label, blinded-endpoint
PROBE) design [20]. The study consists of two parallel arms
f antihypertensive treatments, i.e. valsartan-based vs.
mlodipine-based. The study was registered at ClinicalTri-
ls.gov (http://www.clinicaltrials.gov/) with the identiﬁer
CT00129233.
tudy population
atients who were between 30 and 75 years old and had
oth hypertension and glucose intolerance (IGT or T2DM)
ere eligible to be enrolled in the NAGOYA HEART Study.
atients were considered as hypertensive when they were
lready taking antihypertensive drugs or when they had sys-
olic or diastolic blood pressure equal to or more than 140 or
0mmHg, respectively, on at least two different occasions
espite education about appropriate lifestyle modiﬁcation.
lucose intolerance consists of T2DM or IGT, which were
eﬁned according to the statement from the American Dia-
etes Association [21]. In brief, T2DM was deﬁned when
ubjects had already been taking drugs for T2DM, fast-
ng glucose equal to 126mg/dL or more, or non-fasting
lucose or glucose 2 hr after 75 g oral glucose tolerance
est (OGTT) equal to 200mg/dL or more. IGT was deﬁned
y glucose between 140 and 199mg/dL at 2 h after the
GTT. We included patients with IGT but not those with
mpaired fasting glucose (IFG), since individuals with IGT
ave a similar risk of cardiovascular disease as diabetic
atients, but the risk of subjects with IFG is approxi-
ately that of individuals with normal glucose tolerance
22].
Patients with the following conditions at enrollment were
xcluded: (1) history of heart failure, myocardial infarction,
oronary revascularization (percutaneous coronary inter-
ention or coronary artery bypass graft surgery), or stroke
n the last 6 months; (2) patients who were taking CCBs for
he purpose of the suppression of angina pectoris includ-
ng coronary spastic angina; (3) impaired left ventriculariastolic blood pressure greater than 200 or 110mmHg,
espectively) or secondary hypertension; (6) serum creati-
ine equal to 2.5mg/dL or more; (7) estimated prognosis
ess than 3 years due to other conditions; (8) pregnant
omen or women with a potential of childbearing; (9) other
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sFigure 1 Titration schedule of the assigned drugs for the NAG
excluding ACEIs, ARBs, and CCBs.
conditions by which physicians in charge judged inappropri-
ate to enroll because of patients’ safety concern.
Informed consent
Participating centers included 46 afﬁliated hospitals led
by cardiology specialists in Nagoya City and its vicinity.
All participants provided their written informed consent
after receiving explanations by a physician in charge about
study objectives, study protocol, possible adverse effects
of the study drugs, measures for privacy protection, and
study withdrawal. The Ethics Review Committee of Nagoya
University School of Medicine and the Committee at each
participating center approved the study protocol.
Study procedures
Randomization was automatically performed by a host com-
puter system using the minimization method. The treatment
protocol of the NAGOYA HEART Study is shown in Fig. 1. The
initial doses are 80mg/day for valsartan and 5mg/day for
amlodipine, respectively. Physicians increased doses until
160mg or 10mg per day, respectively, as needed. Also,
diuretics, -blockers, or -blockers can be added to achieve
target blood pressure for hypertensive patients with dia-
betes (i.e. 130/80mmHg). For participants already taking
antihypertensive drugs at the enrollment, ACEIs, ARBs, and
CCBs were discontinued, and the allocated drug was pre-
scribed without a run-in period. Diuretics, -blockers or
-blockers could be continued when physicians considered
appropriate. Clinical care for T2DM/IGT was conducted
according to the guidelines of the Japanese Diabetes Society
[23].Measurements of interest
Demographic variables such as sex, age, smoking status,
co-morbidities including dyslipidemia, T2DM/IGT, and a
d
o
d
u
mEART Study. Asterisk (*) indicates other antihypertensive drugs
ast history of cardiovascular disease were obtained at
aseline. Also, physiological ﬁndings including blood pres-
ure, anthropometry, blood examination, electrocardiogram
ECG), and echocardiogram were evaluated at baseline. The
bove measurements were repeated every 6 months except
or echocardiogram, which was carried out once a year.
he blood examination included the following items: fast-
ng glucose, hemoglobin A1c, low-density and high-density
ipoprotein cholesterols, triglyceride, uric acid, blood urea
itrogen, serum creatinine, sodium, and potassium. The
ollow-up OGTT was conducted every year only for sub-
ects with IGT. During an echocardiogram, the following
ariables were measured: dimension of the left ventricle at
oth end-diastole and end-systole, thickness of the inter-
entricular septum and left ventricular posterior wall at
nd-diastole, left ventricular ejection fraction, the ratio of
arly ventricular ﬁlling to atrial contraction velocity (E/A
atio).
valuation of outcomes
he primary endpoint is a composite of cardiovascular
orbidity and mortality. Components of the primary end-
oint include the following: (1) myocardial infarction (ECG
hange, elevation of cardiac enzymes, and culprit lesion
etected by coronary angiogram); (2) stroke (neurolog-
cal deﬁcit persisting for more than 24 h and relevant
ndings in computed tomography or magnetic resonance
maging); (3) admission due to congestive heart failure (clin-
cal symptoms including dyspnea, shortness of breath, and
eripheral edema, together with pulmonary congestion in
hest roentgenogram); (4) coronary revascularization (per-
utaneous coronary intervention or coronary bypass graft
urgery unplanned at randomization); or (5) sudden car-
iac death (unexpected death within 24 h after the onset
f symptoms). Any of these events must be strictly adju-
icated by an independent Endpoint Evaluation Committee
nder the blinded circumstance regarding assigned treat-
ent.
114 K. Matsushita et al.
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The followings are classiﬁed as the secondary end-
oints: (1) all-cause mortality; (2) glucose control and
ncident T2DM; (3) incident atrial ﬁbrillation or ﬂutter
etected by ECG; (4) change in kidney function (doubling
f plasma creatinine levels and transition to dialysis); and
5) change in cardiac function evaluated by echocardio-
ram.
The follow-up will be conducted every month in the
rst 3 months and every 1—3 months after then accord-
ng to physicians’ decisions and will be terminated when
he ﬁrst event among the primary outcomes occurs. Par-
icipating physicians will obtain information about clinical
utcomes from patients or their families and report those
o the Data Management Group of the NAGOYA HEART
tudy.
tudy organization
he study organization is shown in Fig. 2. The Executive
ommittee created the protocol of the NAGOYA HEART Study
nd observes the progress comprehensively. The Steering
ommittee approved the study protocol and makes a deci-
ion about the management of the study. The Data and
afety Monitoring Board consists of a physician, an epi-
emiologist, an endocrinologist, and a cardiologist and
rovides the Steering Committee with advice when there
re any concerns about participants’ safety. The Endpoint
valuation Committee comprised a cardiologist, a vascular
urgeon, and a neurologist, and they adjudicated primary
ndpoints reported from physicians. The data are collected
hrough the Internet into a secure server and are centrally
anaged by the independent Data Management Group.
he Statistical Analysis Board will perform all statistical
nalyses independently from any of the above commit-
ees.
c
A
a
c
gof the NAGOYA HEART Study.
ample size and statistical analysis
n the Hisayama study, incidence rate of coronary heart
isease (myocardial infarction and sudden cardiac death)
nd stroke among Japanese patients with T2DM was 5.0
nd 6.5 per 1000 person-years [24]. In the Japan Diabetes
omplications Study (JDCS), incidence rate of coronary
eart disease consisting of angina pectoris and myocardial
nfarction, and brain infarction were 6.7 and 6.5 per 1000
erson-years, respectively [25]. Since myocardial infarction,
nstable/stable angina pectoris requiring revascularization,
ongestive heart failure, sudden cardiac death, and stroke
ere all included as a primary composite endpoint in the
resent study and all participants had hypertension, we
stimated at least 5—8% of participants would have car-
iovascular events each year. Under the assumption that
alsartan can reduce cardiovascular events by 20% and the
edian follow-up time would be 3 years, sample size for
ach group was estimated to be 1500 with a two-sided ˛
evel of 0.05 and statistical power of 80%.
Patients’ enrollment began in October 2004 and was
nticipated to be ﬁnished by the end of 2006. Of 1168
atients eligible for the recruitment of the present study,
e had recruited 1150 patients by the end of January
009, when the Data and Safety Monitoring Board sug-
ested stopping patient recruitment due to relatively longer
ecruitment period than anticipated. Consequently, the
teering Committee decided not to recruit patients after
ebruary 2009 and to follow-up participants until median of
ollow-up period reaches more than 3 years.
Analyses will be performed by an independent Statisti-
al Analysis Board based on the intention-to-treat approach.
ll randomized patients (n = 1150) were included in the
nalysis. Cox proportional hazard model will be used for
omparing the difference in risk between the two treatment
roups.
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Discussion
The NAGOYA HEART Study (the NHS) is the ﬁrst large-
scale clinical trial comparing an ARB, valsartan, and a
CCB, amlodipine, speciﬁcally among Japanese hypertensive
patients with glucose intolerance (IGT or T2DM). The beneﬁt
of ACEIs/ARBs compared to CCBs with respect to prevention
of major cardiovascular events among diabetic hypertensive
patients was mainly demonstrated in relatively small studies
with participants <500 such as the ABCD or the FACET Trials
[5,8]. However, no superiority of ACEIs/ARBs with respect to
the prevention of macrovascular disease has been shown in
larger clinical studies (e.g. the ALLHAT or the IDNT) [9,26].
More importantly, the Blood Pressure Lowering Treatment
Trialists’ Collaboration (BPLTTC) investigators conducted a
meta-analysis to elucidate this issue, and they found that
ACEIs were equivalent to CCBs regarding protection against
composite cardiovascular events in hypertensive patients
with T2DM [19]. Only few studies had compared ARBs and
CCBs directly at this moment.
This meta-analysis included only one clinical study from
Asia, that was the Japan Multicenter Investigation for Car-
diovascular Diseases-B (JMIC-B) trial [19]. This JMIC-B trial
compared ACEIs and a CCB, long-acting nifedipine, among
1650 Japanese hypertensive patients and could not show
any signiﬁcant difference in cardiovascular events in the
two treatment arms during 3-year follow-up period [27].
Since the JMIC-B included only 372 patients with T2DM,
Asian population with both hypertension and T2DM has
been understudied. Therefore, although we could not enroll
a priori planned number of patients, we anticipate that
the NAGOYA HEART Study will provide us with clinically
relevant information regarding appropriate treatment of
hypertension with glucose intolerance among an East Asian
population.
ACEIs and ARBs are considered particularly effective to
protect renal function [1,4]. Indeed, a number of studies
have reported that these two types of drugs can prevent
deterioration of glomerular ﬁltration rate and deterioration
of proteinuria [28]. However, a meta-analysis conducted by
Casas and colleagues demonstrated that the effectiveness
of ACEIs and ARBs is clearly shown in small studies with par-
ticipants <500 but is less evident in larger clinical studies
[28]. Typically, the ALLHAT including ≈13,000 patients with
T2DM of more than 30,000 hypertensive patients did not
show a superior beneﬁt of an ACEI, lisinopril, compared to
amlodipine or a thiazide-type diuretic with respect to renal
protection [26,28]. Interestingly, when four clinical stud-
ies comprising only diabetic patients were combined, the
occurrence of end-stage renal disease was not statistically
different between ACEIs/ARBs and other antihypertensive
drugs [28]. Thus, renal protective effects of ACEIs/ARBs
beyond lowering blood pressure remain to be proved [28].
This is particularly the case for Japanese. The Japan Mul-
ticenter Investigation of Antihypertensive Treatment for
Nephropathy in Diabetics (J-MIND) Study reported that a
CCB, nifedipine, was similarly protective against deteri-
oration of albuminuria compared to an ACEI, enalapril,
among 438 Japanese diabetic hypertensive patients. Thus,
the NAGOYA HEART study will provide us relevant informa-
tion regarding renal protection by antihypertensive drugs
among Japanese.
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After the NAGOYA HEART Study was initiated, a few
tudies investigated whether an ARB is superior to a
CB regarding risk reduction of cardiovascular diseases.
he VALUE trial compared the effects of valsartan- and
mlodipine-based regimens among 15,245 hypertensive
atients aged 50 years or older and reported that there
as no statistical difference in the two treatment groups
or the prevention of cardiovascular events [29]. The risk
f myocardial infarction and stroke tended to be lower
n the amlodipine-based treatment group compared to
he valsartan group. The authors raised a possibility that
igniﬁcantly lower blood pressure levels achieved in the
mlodipine group might contribute to the lower cardio-
ascular incidences. Similarly, Ogihara and colleagues have
ecently reported that there was no statistical differ-
nce in the risk of cardiovascular morbidity and mortality
etween ARB candesartan-based and amlodipine-based reg-
mens among 4728 Japanese hypertensive patients enrolled
n the Candesartan Antihypertensive Survival Evaluation in
apan (CASE-J) Trial [30,31]. Although the CASE-J trial has
hown that an ARB-based regimen may be beneﬁcial particu-
arly in obese patients, results speciﬁc to T2DM participants,
3% of the entire study population, have not been reported
30,31].
In contrast, Mochizuki and colleagues reported 40%
eduction of the risk for their primary composite endpoint
i.e. composite of cardiovascular mortality and morbidity)
ith valsartan compared to non-ARB treatment group in the
IKEI HEART Study including 3081 Japanese patients with
ypertension, coronary heart disease, or heart failure [32].
imilarly, the KYOTO HEART Study reported 45% reduction
f incident cardiovascular disease by valsartan as compared
ith non-ARB treatment in Japanese patients with hyper-
ension [33]. The precise reasons of the inconsistent results
bserved among these studies are under debate [34,35].
he fact that there was no evident control drug in the JIKEI
EART Study might explain the results. In fact, participants
n the non-ARB group in the JIKEI HEART Study tended to
ake less antihypertensive drugs than those in the valsar-
an group in the ﬁrst 2-year follow-up [32]. Furthermore,
ince the JIKEI HEART Study recruited not only patients with
ypertension but also those with heart failure and coronary
eart disease, a part of patients with certain characteristics
e.g. prevalent heart failure) might receive speciﬁc beneﬁts
f an ARB-based regimen.
Taken together, since it is still unclear whether an ARB
s superior to a CCB with respect to the prevention of car-
iovascular events among Japanese diabetic hypertensive
atients, the results of the NAGOYA HEART Study will be
uite valuable.
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